Yenovus Pharma Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 4.96 Cr
as on 22-12-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 19.56 Cr
as on 22-12-2024
- Revenue 208.05%
(FY 2021)
- Profit -85.49%
(FY 2021)
- Ebitda -47.36%
(FY 2021)
- Net Worth -280.24%
(FY 2021)
- Total Assets 5.42%
(FY 2021)
About Yenovus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.96 Cr.
The company has closed loans amounting to ₹19.56 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Velayutharaja Balasubramanyam and Bala Vivek serve as directors at the Company.
- CIN/LLPIN
U24290AP2016PTC103314
- Company No.
103314
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 May 2016
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Yenovus Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bala Vivek  | Director | 23-May-2016 | Current |
| Velayutharaja Balasubramanyam | Director | 23-May-2016 | Current |
Financial Performance of Yenovus Pharma.
Yenovus Pharma Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 208.05% increase. The company also saw a substantial fall in profitability, with a 85.49% decrease in profit. The company's net worth observed a substantial decline by a decrease of 280.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Yenovus Pharma?
In 2021, Yenovus Pharma had a promoter holding of 97.98% and a public holding of 2.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Micro Molecules Private LimitedActive 21 years 8 monthsVelayutharaja Balasubramanyam and Bala Vivek are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Jan 2022 | ₹1.70 Cr | Satisfied |
Others Creation Date: 05 Mar 2018 | ₹17.86 Cr | Satisfied |
How Many Employees Work at Yenovus Pharma?
Yenovus Pharma has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Yenovus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yenovus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
